{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:14:35Z","timestamp":1790295275645,"version":"4.1.0"},"reference-count":18,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,10]]},"DOI":"10.2967\/jnumed.125.269863","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:35:12Z","timestamp":1756398912000},"page":"1581-1588","source":"Crossref","is-referenced-by-count":7,"title":["Diagnostic Performance of the <sup>68<\/sup>Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors"],"prefix":"10.2967","volume":"66","author":[{"given":"Christian","family":"Uprimny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"von Guggenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sviridenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Bayerschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Maria","family":"Rossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessamoddin","family":"Roustaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Warwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene J.","family":"Virgolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"2025100106250830000_66.10.1581.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.221283"},{"key":"2025100106250830000_66.10.1581.2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00259-020-04963-z","article-title":"Comparison of PET\/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma","volume":"48","author":"Uprimny","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025100106250830000_66.10.1581.3","first-page":"1377","article-title":"Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors","volume":"57","author":"Reubi","year":"1997","journal-title":"Cancer Res."},{"key":"2025100106250830000_66.10.1581.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0157-8"},{"key":"2025100106250830000_66.10.1581.5","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01245"},{"key":"2025100106250830000_66.10.1581.6","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s11864-023-01145-5","article-title":"The evolving treatment landscape of medullary thyroid cancer","volume":"24","author":"Lagan\u00e0","year":"2023","journal-title":"Curr Treat Options Oncol."},{"key":"2025100106250830000_66.10.1581.7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary thyroid cancer: updates and challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr Rev."},{"key":"2025100106250830000_66.10.1581.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-2031-6"},{"key":"2025100106250830000_66.10.1581.9","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s11912-024-01526-5","article-title":"Radionuclide theranostics in neuroendocrine neoplasms: an update","volume":"26","author":"Di Franco","year":"2024","journal-title":"Curr Oncol Rep."},{"key":"2025100106250830000_66.10.1581.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268877"},{"key":"2025100106250830000_66.10.1581.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264977"},{"key":"2025100106250830000_66.10.1581.12","first-page":"P242","article-title":"Evaluation of [68Ga]Ga-DOTA-CP04 imaging in cholecystokinin-2 receptors (CCK-2R) positive tumors [abstract]","volume":"64","author":"Kong","year":"2023","journal-title":"J Nucl Med."},{"key":"2025100106250830000_66.10.1581.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266537"},{"key":"2025100106250830000_66.10.1581.14","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/RLU.0000000000005355","article-title":"Biodistribution and radiation dosimetry for 68Ga-DOTA-CCK-66, a novel CCK2R-targeting compound for imaging of medullary thyroid cancer","volume":"49","author":"Viering","year":"2024","journal-title":"Clin Nucl Med."},{"key":"2025100106250830000_66.10.1581.15","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00259-022-05992-6","article-title":"[111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC phase I clinical trial","volume":"50","author":"Lezaic","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025100106250830000_66.10.1581.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233031"},{"key":"2025100106250830000_66.10.1581.17","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1007\/s00259-024-06749-z","article-title":"Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET\/CT in a patient with extensive disease small cell lung cancer","volume":"51","author":"Di Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025100106250830000_66.10.1581.18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-024-06979-1","article-title":"Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy","volume":"52","author":"Zavvar","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:25:38Z","timestamp":1759325138000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":18,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,1]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.2967\/jnumed.125.269863"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269863","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]}}}